High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
A Chinese humanoid maker just pulled off one of the most frenzied IPOs in recent memory, and the shockwaves are now rippling through U.S. robotics stocks in a big way. Here is what traders are watching as the physical AI theme hits a new gear.
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.
OpenAI has reportedly completed a deal to help employees sell nearly $7 billion worth of the company’s shares ahead of its potential IPO. The Sam Altman-led company repurchased shares from existing as well as former employees rather than relying on...
Ark Invest on Monday said that SPCX’s 14% drop on Wednesday last week overlooked SpaceX’s $28.5 trillion total addressable market outlined in its IPO filings.
Initial public offerings won't unlock instant wealth for retail investors.
The newly public companies offer investors a choice between the hot space sector and the emerging quantum computing market.
Loar stock sets up a new buy point amid the recent market strength. The aerospace and defense giant is looking for support at a key level.
Wall Street Says AMD's Taalas Deal Won't Close Nvidia's AI Gap
(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at the top of a marketed range.Most Read from BloombergOpenAI’s New Device Will Be Hockey Puck-Sized and Cost Over $300Iran Wants to Bar US, Israeli Ships From Hormuz in Peace AccordIran Says Agreement on Hormuz Shipping Reached With OmanTrump Administration Considers Order on Autism and VaccinesWhy D
Stock market leaders are becoming plentiful as the S&P 500 probes all-time highs. Recent IPO Bending Spoons clears an IPO base.
SPCX stock climbed 6% on Thursday despite 911.5 million shares becoming eligible for sale after a lockup expired.
Investing.com -- Roku Inc (NASDAQ:ROKU) reported second quarter results that exceeded analyst expectations, with adjusted earnings per share of $1.08 compared to the consensus estimate of $0.60, and revenue of $1.35 billion versus the $1.3 billion estimate.
AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff on Monday when the merger speculation first emerged, while BMY shareholders were widely viewed as the primary beneficiaries of any combination.
Is Chipotle facing another food safety crisis?
The Ark Invest founder is betting big on SpaceX.
Suze Orman walked through a real SpaceX IPO trade that turned $10,000 into roughly $5,600 in seven weeks, and her lesson has nothing to do with rockets or Elon Musk.
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
Which of these three high-tech market newcomers is the best?
Is the hot IPO stock finally a bargain?
Video podcasting and gaming could be revenue generators for Netflix, but there isn't anything on the immediate horizon to help reverse stock price losses.
The new CEO took over the conglomerate with a massive nest egg that he must try to deploy.
Chipotle shares shot up after strong Q2 earnings, but Starbucks stock could be the better buy.
(Bloomberg) -- Apnimed Inc., a late-stage drug developer focused on sleep apnea rose 6.3% on Friday after raising $192 million in an upsized US initial public offering.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesAnthropic AI Models Hacked Three Organizations During TestsMicrosoft’s $450 Billion Jump Is Biggest in Stock Market HistoryChip Stocks Post Biggest Advance Since April 2025: Markets WrapUS Strikes Iran Again as Conflict Spreads Across Middle Ea
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
The IPO market has made an impressive comeback this year. Momentum began building in the first quarter and accelerated in the second, with traditional IPOs raising $114.1 billion through June 30, 2026 – roughly seven times the amount raised during the first half of 2025. SpaceX, the largest IPO in Wall Street history, understandably dominated the headlines and made Elon Musk the world’s first trillionaire, but the strength of the market extended well beyond a single blockbuster listing.Claim 55%
A China carveout could reduce regulatory complications related to SpaceX’s U.S. defense work and possible Beijing scrutiny.
A China carveout could reduce regulatory complications related to SpaceX’s U.S. defense work and possible Beijing scrutiny.
A China carveout could reduce regulatory complications related to SpaceX’s U.S. defense work and possible Beijing scrutiny.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
